| Ticker: | SLNO |
| Current Price: | $53.01 |
| % Daily Change: | 0.00% |
| Volume (1,000s): | 4,968.83 |
| Average Volume (1,000s): | 3,449.57 |
| Market Cap (M): | $2,762.89 |
Soleno Therapeutics, Inc.
203 Redwood Shores Parkway
Suite 500
Redwood City, CA 94065
United States
At Soleno, we are researching and developing medicines to treat rare genetic disorders, beginning with Prader-Willi syndrome (PWS), a life-threatening neurobehavioral, metabolic and endocrine disorder characterized by hyperphagia (insatiable hunger), neurocognitive and behavioral difficulties. Our lead candidate, DCCR, is a Phase 3, once-daily oral tablet under investigation as a potential treatment for PWS. Our priority is to bring the first approved treatment to patients to manage the most burdensome aspects of this devastating disorder.